Physician profile
Stephen M Abo
NPI 1891717708
$2,820.09
in general payments reported to CMS, 2019-2025
16 companies · $646 in 2025
The $646 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $13.66 · 2021: $41.11 · 2022: $248 · 2023: $193 · 2024: $1,508 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,631 · Food and Beverage: $516 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,630.90 |
| Food and Beverage | $516.07 |
| Education | $199.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,645.92 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $380.63 | 2019-2025 | Lynparza |
| Astellas Pharma US INC | $199.90 | 2022 | |
| Janssen Biotech, INC. | $160.20 | 2019-2024 | Darzalex |
| Incyte Corporation | $116.95 | 2024-2025 | Jakafi |
| Genzyme Corporation | $92.84 | 2024-2025 | |
| Amgen INC. | $53.56 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Mirati Therapeutics, INC. | $31.16 | 2023 | Krazati |
| Lilly USA, LLC | $29.04 | 2019 | |
| Pharmacosmos Therapeutics INC. | $19.19 | 2023 | Monoferric |
| Taiho Oncology, INC. | $18.86 | 2025 | |
| Daiichi Sankyo INC. | $16.15 | 2025 | Datroway |
| Octapharma USA, INC. | $15.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.25 | 2021 | |
| Pfizer INC. | $14.07 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Abo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.